<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04599803</url>
  </required_header>
  <id_info>
    <org_study_id>102033</org_study_id>
    <nct_id>NCT04599803</nct_id>
  </id_info>
  <brief_title>Baseline Sleep Apnea Study #2</brief_title>
  <official_title>Baseline Sleep Apnea Study #2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verily Life Sciences LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verily Life Sciences LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single group, unblinded, prospective clinical study. This study seeks to understand&#xD;
      patient diagnostic and treatment journey and positive airway pressure (PAP) therapy&#xD;
      compliance for Verily Sleep Apnea (VSA) program/app users. Participants will enroll remotely&#xD;
      and may undergo a home sleep test (HST). Upon confirmation of obstructive sleep apnea (OSA)&#xD;
      and prescription of PAP therapy, the participant will begin using the VSA app to supplement&#xD;
      PAP treatment. After 90 days of active participation, the participant will be given&#xD;
      instructions for follow-up care, as indicated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time (number of days) from when participant is told they may have OSA to when they receive HST prescription</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time (number of days) from when participant receives HST prescription to when they receive their diagnosis</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time (number of days) from OSA diagnosis to PAP therapy initiation</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time (number of days) from therapy initiation to when 90-day compliance threshold is achieved</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Completion rates among individuals who had an HST ordered</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of individuals who completed the HST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion rates among individuals prescribed a PAP device</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of individuals who filled the order (PAP device delivered to them)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion rates among individuals prescribed a PAP device</measure>
    <time_frame>90 days</time_frame>
    <description>Percentage of individuals who used the PAP device at least once during the 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of participants who meet 90 day compliance success criteria</measure>
    <time_frame>90 days</time_frame>
    <description>Compliance Metrics - Percent of participants who meet 90 day compliance success criteria, as defined by: â‰¥ 4 hours per night on 70% of nights during a consecutive 30 day period anytime during the first 90 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Obstructive Sleep Apnea of Adult</condition>
  <arm_group>
    <arm_group_label>Participants diagnosed with Obstructive Sleep Apnea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This will be a single arm study of participants that are diagnosed with Obstructive Sleep Apnea (OSA) during the study. Upon confirmation of OSA and prescription of positive airway pressure (PAP) therapy, the participant will begin using the Verily Sleep Apnea (VSA) app to supplement PAP treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Verily Sleep Apnea (VSA) Program/App</intervention_name>
    <description>The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.</description>
    <arm_group_label>Participants diagnosed with Obstructive Sleep Apnea</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 18 or older&#xD;
&#xD;
          -  Able to speak and read English&#xD;
&#xD;
          -  Legal United States Resident with a Government Issued ID&#xD;
&#xD;
          -  Participating in the Project Baseline Community Study&#xD;
&#xD;
          -  Demonstrates understanding of the study requirements and is able and willing to sign&#xD;
             the informed consent form&#xD;
&#xD;
          -  Own a smartphone with a data plan and be the primary user of the smartphone;&#xD;
             smartphone must use Android Lollipop (5.1+/ API 22+) or iOS 11.X+&#xD;
&#xD;
          -  Own a computer with a web camera&#xD;
&#xD;
          -  Consistent access to electricity and wifi for the duration of the study&#xD;
&#xD;
          -  Have a high risk of OSA as determined by screening questionnaire&#xD;
&#xD;
          -  Good candidate for PAP therapy, in the opinion of the managing clinician&#xD;
&#xD;
          -  Without significant limitation in ability to participate in the study, in the opinion&#xD;
             of the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously diagnosed with sleep apnea or other sleep disorders, that in the opinion of&#xD;
             the investigator, makes the participant ineligible (e.g., Obstructive Sleep Apnea,&#xD;
             Central Sleep Apnea, Complex Sleep Apnea, chronic insomnia)&#xD;
&#xD;
          -  Participant is a shift worker (indicated by having a night shift schedule on a regular&#xD;
             basis, or a work shift that changes or rotates on a daily, weekly, or monthly basis)&#xD;
&#xD;
          -  Sponsor employees and individuals working on Project Baseline&#xD;
&#xD;
          -  Self reported to be pregnant or planning to become pregnant during the study period&#xD;
&#xD;
          -  Current use of home oxygenation devices, such as supplemental oxygen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Verily Life Sciences LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Verily Life Sciences LLC</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

